Bispecific CD16-Binding Molecules and Their Use in the Treatment of Disease
AssigneeMacroGenics, Inc.
InventorsGundo Diedrich, Liqin Liu, Hua Watson Li, Leslie S. Johnson
Life of this patent
Estimating the term…
Loading patent…
AssigneeMacroGenics, Inc.
InventorsGundo Diedrich, Liqin Liu, Hua Watson Li, Leslie S. Johnson
Estimating the term…
The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen (“DA”) (e.g., a “CD16 x DA Binding Molecule”). The present invention is particularly directed to such CD16 x DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16 x DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16 x DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).
A CD16 x Disease Antigen (CD16 x DA) Binding Molecule comprising a CD16 Binding Domain capable of binding an epitope of CD16 and also a Disease Antigen-Binding Domain capable of binding an epitope of a Disease Antigen, wherein said CD16 Binding Domain comprises one or more of:
A CD16 Binding Molecule, that comprises:
A CD16 Binding Molecule that comprises:
The use or method of claim 35, wherein said Disease Antigen is an HIV env antigen.
Dependencies are inferred from the claim text.